Development and validation of a new comorbidity index for patients with head and neck squamous cell carcinoma in Japan

Abstract Due to habitual drinking and smoking and advanced age at diagnosis, patients with head and neck squamous cell carcinoma (HNSCC) frequently present with comorbidities. Several comorbidity indices have been developed and validated for HNSCC. However, none have become the standard method. In t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yukinori Takenaka, Norihiko Takemoto, Ryohei Oya, Naoki Ashida, Takahiro Kitamura, Kotaro Shimizu, Kazuya Takemura, Takahiro Michiba, Atsushi Hanamoto, Motoyuki Suzuki, Yoshifumi Yamamoto, Atsuhiko Uno, Hidenori Inohara
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/da4c033e18454237b549f73d27f257ed
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:da4c033e18454237b549f73d27f257ed
record_format	dspace
spelling	oai:doaj.org-article:da4c033e18454237b549f73d27f257ed2021-12-02T15:06:14ZDevelopment and validation of a new comorbidity index for patients with head and neck squamous cell carcinoma in Japan10.1038/s41598-017-07752-12045-2322https://doaj.org/article/da4c033e18454237b549f73d27f257ed2017-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-07752-1https://doaj.org/toc/2045-2322Abstract Due to habitual drinking and smoking and advanced age at diagnosis, patients with head and neck squamous cell carcinoma (HNSCC) frequently present with comorbidities. Several comorbidity indices have been developed and validated for HNSCC. However, none have become the standard method. In this study, we developed a new comorbidity index for Japanese patients with HNSCC, which was validated against an independent data set. A Cox proportional hazards analysis of 698 patients identified dementia, connective tissue diseases, and second primary malignancies in the oesophagus, head and neck, lungs, and stomach as prognostic comorbidities for overall survival. The Osaka head and neck comorbidity index (OHNCI) was generated from the weighted points of these comorbidities. In the independent data set, the 5-year overall survival rates for the low, moderate, and high scoring OHNCI groups were 62.1%, 64.3%, and 37.7%, respectively. In the multivariate analysis, the high scoring OHNCI group was an independent prognostic factor for overall survival (hazard ratio: 1.81, 95% confidence interval: 1.05–3.13; P = 0.031). The model including the OHNCI exhibited a higher prognostic capability compared to those including other commonly used comorbidity indices. The OHNCI could become the primary choice for comorbidity assessment in patients with HNSCC in Japan.Yukinori TakenakaNorihiko TakemotoRyohei OyaNaoki AshidaTakahiro KitamuraKotaro ShimizuKazuya TakemuraTakahiro MichibaAtsushi HanamotoMotoyuki SuzukiYoshifumi YamamotoAtsuhiko UnoHidenori InoharaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-11 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yukinori Takenaka Norihiko Takemoto Ryohei Oya Naoki Ashida Takahiro Kitamura Kotaro Shimizu Kazuya Takemura Takahiro Michiba Atsushi Hanamoto Motoyuki Suzuki Yoshifumi Yamamoto Atsuhiko Uno Hidenori Inohara Development and validation of a new comorbidity index for patients with head and neck squamous cell carcinoma in Japan
description	Abstract Due to habitual drinking and smoking and advanced age at diagnosis, patients with head and neck squamous cell carcinoma (HNSCC) frequently present with comorbidities. Several comorbidity indices have been developed and validated for HNSCC. However, none have become the standard method. In this study, we developed a new comorbidity index for Japanese patients with HNSCC, which was validated against an independent data set. A Cox proportional hazards analysis of 698 patients identified dementia, connective tissue diseases, and second primary malignancies in the oesophagus, head and neck, lungs, and stomach as prognostic comorbidities for overall survival. The Osaka head and neck comorbidity index (OHNCI) was generated from the weighted points of these comorbidities. In the independent data set, the 5-year overall survival rates for the low, moderate, and high scoring OHNCI groups were 62.1%, 64.3%, and 37.7%, respectively. In the multivariate analysis, the high scoring OHNCI group was an independent prognostic factor for overall survival (hazard ratio: 1.81, 95% confidence interval: 1.05–3.13; P = 0.031). The model including the OHNCI exhibited a higher prognostic capability compared to those including other commonly used comorbidity indices. The OHNCI could become the primary choice for comorbidity assessment in patients with HNSCC in Japan.
format	article
author	Yukinori Takenaka Norihiko Takemoto Ryohei Oya Naoki Ashida Takahiro Kitamura Kotaro Shimizu Kazuya Takemura Takahiro Michiba Atsushi Hanamoto Motoyuki Suzuki Yoshifumi Yamamoto Atsuhiko Uno Hidenori Inohara
author_facet	Yukinori Takenaka Norihiko Takemoto Ryohei Oya Naoki Ashida Takahiro Kitamura Kotaro Shimizu Kazuya Takemura Takahiro Michiba Atsushi Hanamoto Motoyuki Suzuki Yoshifumi Yamamoto Atsuhiko Uno Hidenori Inohara
author_sort	Yukinori Takenaka
title	Development and validation of a new comorbidity index for patients with head and neck squamous cell carcinoma in Japan
title_short	Development and validation of a new comorbidity index for patients with head and neck squamous cell carcinoma in Japan
title_full	Development and validation of a new comorbidity index for patients with head and neck squamous cell carcinoma in Japan
title_fullStr	Development and validation of a new comorbidity index for patients with head and neck squamous cell carcinoma in Japan
title_full_unstemmed	Development and validation of a new comorbidity index for patients with head and neck squamous cell carcinoma in Japan
title_sort	development and validation of a new comorbidity index for patients with head and neck squamous cell carcinoma in japan
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/da4c033e18454237b549f73d27f257ed
work_keys_str_mv	AT yukinoritakenaka developmentandvalidationofanewcomorbidityindexforpatientswithheadandnecksquamouscellcarcinomainjapan AT norihikotakemoto developmentandvalidationofanewcomorbidityindexforpatientswithheadandnecksquamouscellcarcinomainjapan AT ryoheioya developmentandvalidationofanewcomorbidityindexforpatientswithheadandnecksquamouscellcarcinomainjapan AT naokiashida developmentandvalidationofanewcomorbidityindexforpatientswithheadandnecksquamouscellcarcinomainjapan AT takahirokitamura developmentandvalidationofanewcomorbidityindexforpatientswithheadandnecksquamouscellcarcinomainjapan AT kotaroshimizu developmentandvalidationofanewcomorbidityindexforpatientswithheadandnecksquamouscellcarcinomainjapan AT kazuyatakemura developmentandvalidationofanewcomorbidityindexforpatientswithheadandnecksquamouscellcarcinomainjapan AT takahiromichiba developmentandvalidationofanewcomorbidityindexforpatientswithheadandnecksquamouscellcarcinomainjapan AT atsushihanamoto developmentandvalidationofanewcomorbidityindexforpatientswithheadandnecksquamouscellcarcinomainjapan AT motoyukisuzuki developmentandvalidationofanewcomorbidityindexforpatientswithheadandnecksquamouscellcarcinomainjapan AT yoshifumiyamamoto developmentandvalidationofanewcomorbidityindexforpatientswithheadandnecksquamouscellcarcinomainjapan AT atsuhikouno developmentandvalidationofanewcomorbidityindexforpatientswithheadandnecksquamouscellcarcinomainjapan AT hidenoriinohara developmentandvalidationofanewcomorbidityindexforpatientswithheadandnecksquamouscellcarcinomainjapan
_version_	1718388546095546368

Development and validation of a new comorbidity index for patients with head and neck squamous cell carcinoma in Japan

Ejemplares similares